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We prospectively assessed the diagnostic value of pleural fluid complement levels (total, C3,
C4) in 135 patients with pleural effusion of five main etiologies, using novel markers.
Complement levels correlated with pleural levels of protein, amylase, and transuded fluids.
On univariate analysis, CHF-related pleural effusions were associated with significantly lower
C4 levels than postsurgery or parapneumonic effusions. On multivariate analysis, pleural fluid
C4 level was a significant predictor of CHF. Although the specificity, positive predictive value,
and accuracy of the parameters were low in all diagnostic groups, their negative predictive
value as well as the AUC ROC was high for CHF and post-LTX. We conclude that pleural fluid
C4 levels can differentiate CHF-related pleural effusion from other etiologies and that normal
level of C3 or C4 rule out CHF or LTX as causes of pleural effusion. Complement should be
included in the assessment of pleural effusion when traditional diagnostic methods fail.
ª 2008 Published by Elsevier Ltd.Introduction
Pleural effusion is a common complication of a variety of
local and systemic diseases. The most common causes are
malignancy, infection, tuberculosis, pulmonary embolism,
congestive heart failure (CHF), and systemic autoimmunery Institute, Rabin Medical
wa 49100, Israel. Tel.: þ972
.il (D. Shitrit).
8 Published by Elsevier Ltd.disease.1 In about one-third of cases, the cause remains
unknown, despite thorough examination.2
Complement activation may be measured by monitoring
the total complement and the C3 or C4 components of the
cascade.3 Several studies have reported the activation of
complement in the pleural fluid of patients with rheuma-
toid arthritis4e7 and tuberculosis.8,9 However, the associa-
tion between complement activation and the cause of
pleural effusion has not been thoroughly examined.
By measuring concentrations both of various components
of complements and of their activation products, it is
possible to decide which pathway is prevailing. High levels
1632 D. Shitrit et al.of C4activation product (C4d) reflect classic pathway
activation, and high levels of factor B activation product
(Bb) reflect alternative pathway activation. When either the
classic or the alternative pathway is activated, the concen-
trations of C3activation product (C3d) and C5be9 are
increased.Detectionof complement complexesor fragments
in pleural fluids directly indicates complement activation.
The aim of this study was to determine the value of
complement component measures in determining the
underlying cause of pleural effusion.
Patients and methods
Patients
The study population consisted of 135 patients, 79 men
(59%) and 56 women (41%), with pleural effusion who
attended the Pulmonary Institute of Rabin Medical Center
from January 2005 to December 2006. The diagnoses were
divided into five categories on the basis of the underlying
disease/procedure.
e The diagnosis of malignant effusion was made when
malignant cells were found on cytologic examination or in
a biopsy specimen. Patients with negative cytologic findings
were further examined with closed pleural biopsy, and
those with negative findings on closed biopsy underwent
video-assisted thoracoscopic surgery.
e The pleural effusion was considered parapneumonic if
it was associated with acute febrile illness with purulent
sputum, pulmonary infiltrate, and responsiveness to anti-
biotic treatment, or if the microorganism was identified in
the pleural fluid in the absence of any other cause of the
pleural effusion. Tuberculous pleurisy was diagnosed by
positive cultures for Mycobacterium tuberculosis or when
the pleural biopsy specimen showed typical epithelioid
cell granuloma.
e The pleural effusion was attributed to CHF in patients
in whom CHF was diagnosed by findings of an enlarged
heart, pulmonary venous congestion on the radiograph, and
peripheral edema, with response to CHF treatment and
absence of malignancy or pulmonary infiltrates associated
with an inflammatory process.
e The diagnosis of postcardiotomy or postsurgery
(Dressler’s syndrome) pleural effusion was made when the
pleural fluid developed after injury to the heart, the
patient responded to treatment with anti-inflammatory
agents or corticosteroids, and CHF, pulmonary embolism,
and pneumonia were ruled out.
e The diagnosis of post-LTX pleural effusion was made in
patients who had undergone lung transplantation and had
no evidence of infection, rejection or other known cause of
pleural effusion.
Laboratory studies
Pleural fluid was collected from each patient prior to any
therapy for biochemical, cytological and microbiological
analysis. Supernatant was obtained by centrifugation at
300 rpm for 15 min and stored at 20 C until assayed. The
clinicians who performed the laboratory studies were
blinded to the diagnosis of the pleural effusions.The tumor markers carcinoembryonic antigen (CEA),
cytokeratin fragment (CYFRA) 21e1, cancer antigen (CA)
19e9, CA15e3, and CA 125 were measured by solid-phase,
two-site chemiluminescent enzyme immunometric assays.
Cutoff levels were as follows: CEA, 0e5 ng/ml; CYFRA 21e
1, 0e3.3 ng/ml; CA15e33, 0e30 U/ml; CA 19e9, 0e37 U/
ml; CA 125, 0e35 U/ml.
Total complement and C3 and C4 levels in pleural fluid
were assayed in duplicate using commercially available
sandwich ELISA kits supplied by Progen Biotechnik
(Heidelberg, Germany).
Statistical analysis
Results are shown as mean  standard deviation. Pearson
correlation coefficient (r) and the significance for it (p)
were calculated between the variables. To analyze differ-
ences in the distribution of categorical data, chi-square
test or Fisher exact test was used, as appropriate.
Sensitivity, specificity, positive and negative predictive
values (PPV and NPV), and accuracy of the complement
component levels were calculated between patients with
and without malignancy. Accuracy was defined as (truee
positive þ trueenegative)/(trueepositiveþ falseepositiveþ
trueenegative þ falseenegative).10 The predictive capabil-
ity of each complement variable was demonstrated by
a receiver operator characteristic (ROC) curve. The area
under the curve (AUC) was calculated as a measure of dis-
criminative ability. The higher the AUC values the better
discriminatory ability, as follows: AUC of 0.90 eexcellent
discrimination; 0.80  AUC < 0.90 e good discrimination;
0.70  AUC < 0.80 e fair discrimination; and AUC < 0.70 e
poor discrimination. Differences in mean continuous
variables between the two groups of patients (with and
without malignancy) were analyzed by t-test.
To predict malignancy a stepwise logistic regression was
fitted to the data. Odds ratio and 95% confidence interval
were calculated from the model.
A p value of 0.05 or less was considered statistically
significant.
Results
Table 1 summarizes the clinical and laboratory characteris-
tics of the whole study population (nZ 135) and by
diagnostic group.
No significant differences were noted among the groups
in patient age and sex distribution. The malignancy and
post-LTX groups had predominantly exudative pleural fluid.
The levels of all the pleural markers were significantly
higher in the malignancy group than in the other diagnostic
groups.
The mean concentrations of pleural complement and its
components (C3, C4) were in the low range of normal in all
the diagnostic groups (Table 2), although they were lowest
in the patients with CHF and after LTX. In addition, signif-
icant correlations were noted for the presence of CHF
with C3 level (rZ 0.19, pZ 0.04) and C4 level
(rZ 0.23, pZ 0.01).
On univariate analysis, mean pleural fluid C4 level was
significantly lower in patients with CHF than in patients
Table 1 Clinical characteristics of the study population (nZ 135)
All Malignancy Para-pneumonia CHF Postsurgery LTX
nZ 135 nZ 56 nZ 23 nZ 20 nZ 15 nZ 15
Sex (F/M) 56/79 26/30 11/12 5/10 6/9 7/8
Age, years  SD 67  14 67  14 68  15 66  14 67  16 58  125
Median 67.0 71.5 74.0 67.0 64.0 61.5
Protein, gr% 4.2  1.1 4.6  0.7 4.7  0.9 3.1  1.2 4.7  0.9 2.8  0.6
Median 4.4 4.65 4.9 2.8 4.8 3.0
LDH, mg% 533  622 525  412 984  1210 189  120 497  548 448  237
Median 355.5 374 489.0 158 301.5 359
Glucose, mg% 121  47 109  34 110  42 119  28 129  47 187  73
Median 113 105 106.0 112 121 153
Amylase, mg% 42  22 48  23 36  14 31  13 43  18 33  35
Median 37 45.5 35.5 33 41 23
Trans/exudative (n) 26/109 1/55 2/22 13/7 2/13 8/7
CEA, U/L 88  422 203  640 1.2  0.8 0.9  0.6 0.8  0.5 2.4  2
Median 1.3 3 0.9 0.8 0.6 1.7
CYFRA 21-1, ng% 91  154 143  195 107  159 21  24 22  27 47  78
18.9 29.4 22.8 14.2 16.5 23
CA 15-3, ng% 85  383 181  578 16  8 9  11 12  9 10  5
Median 11.7 20.6 14.55 5.6 8.7 9.9
CA 125, ng% 1231  4581 2099  6997 748  636 652  639 523  473 308  421
Median 491.6 849 418.3 535 260
CA 19-9, ng% 483  4384 1130  6807 1.4  19 3.2  7 4.9  5.9 5.8  14
Median 0.9 1.9 0.6 0.1 3.7 2.7
All data are mean  SD and median. CHFZ congestive heart failure, LTXZ lung transplantation, LDHZ lactate dehydrogenase,
CAZ cancer antigen, CEAZ carcinoembryonic antigen, CYFRAZ cytokeratin fragment.
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(pZ 0.04; pZ 0.01, respectively). On multivariate regres-
sion model, only C4 was a significant predictor of CHF.
Table 3 shows the Pearson correlation coefficient (r) and
the significance for it between complement and clinical
characteristics. C3, C4 and total complement levels all
correlated best with total protein levels, of all the charac-
teristics examined (C3, rZ 0.6, pZ 0.001; C4, rZ 0.56,
pZ 0.001; total C, rZ 0.42, pZ 0.001).
Significant correlations were noted between comple-
ment components and amylase level, tranudate/exudate
data and protein level in pleural fluid (Table 3).
Table 4 showed the sensitivity, specificity, NPV, PPV, and
accuracy of C3, C4 and total complement measurements in
the various diagnostic groups as well as the AUC ROC curve
for no disease. Although the specificity, PPV, and accuracyTable 2 Complement levels by diagnostic groups
Total Malignancy Parapneum
nZ 135 nZ 56 nZ 23
C3 53.3  26 54.5  23 58  24
48.0 50.0 60
C4 12.8  7.2 13.4  7.3 14.8  7.4
12.0 12.0 13.0
Total C 38.8  16 39.2  14 42  21
38.0 38.0 40.5
All data are mean  SD and median. CHFZ congestive heart failure,of the three parameters were low in all the diagnostic
groups, their negative predictive value was high for CHF
and post-LTX pleural effusion (C3, 92% for CHF and 96%
for LTX; C4, 94% for both; total complement, 90% for
both). A relatively high NPV was also found for postcardiot-
omy effusion (C3, 84%; C4, 83%; total complement, 88%). A
relatively high AUC ROC curves for no diseases were also
found for CHF and postcardiotomy effusion (Table 4).
The stepwise regression model showed that none of the
parameters predict malignancy.
Discussion
In clinical practice, clinicians often find it difficult to
identify the cause of pleural effusions. The present study
demonstrates that regardless of the properties of the fluidonia CHF Postsurgery LTX
nZ 20 nZ 15 nZ 15
41  34 58  9 44.8  29
31.0 50.0 34.0
9  7.8 14  5.9 10.7  5
6.0 13.0 10.0
31  14 38  17 37.2  14
29.5 32.0 31.0
LTXZ lung transplantation.
Table 3 Pearson correlation coefficient (r) and the
significance for it (p) between complement components
and clinical variables (nZ 135)
C3 C4 Total C
Protein rZ 0.6 rZ 0.56 rZ 0.42
pZ 0.001 pZ 0.001 pZ 0.0001
Amylase NS rZ 0.21 rZ 0.25
pZ 0.04 pZ 0.02
Transudate/
exudates
rZ 0.37 rZ 0.39 rZ 0.25
pZ 0.0001 pZ 0.001 pZ 0.01
CHFZ congestive heart failure.
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ment could add important diagnostic data.
Earlier studies found that the activation of complement
components in the pleural fluid is associated with autoim-
mune diseases and infections4,6,11,12 Specifically, most of
the patients with pleural effusions secondary to SLE or RA
had reduced levels of pleural fluid complement e total
(CH50) and C3 or C4 components.13,14 Although the findings
did not definitively differentiate patients with SLE or RA
from patients with exudative pleural effusions of other
causes, it was noteworthy that a CH50 level below 10 U/ml,
or a C4 level below 10 times 105 U/g protein, was
detected in most of the patients with autoimmune disease
and rarely in the patients with other diseases. Neverthe-
less, complement levels are no longer recommended to
identify RA- or SLE-related pleural effusions because serum
antibody to nuclear antigen (ANA) levels and rheumatoid
factor (RF) titers appear to be more specific and more
sensitive.15
Several recent studies evaluated the diagnostic utility of
measuring complement activation products in pleural fluid.
Two found that levels of SC5be9, a product of C3Table 4 Sensitivity, specificity, negative and positive predictive
diagnostic group and AUC ROC for no disease
Diagnostic group Sensitivity Specificity
C3 Malignancy 86 22
Parapneumonia 68 16
CHF 90 20
Postsurgery 73 18
Post-LTX 93 22
C4 Malignancy 75 28
Parapneumonia 61 24
CHF 90 30
Postsurgery 60 25
Post-LTX 86 29
Total C Malignancy 61 37
Parapneumonia 48 35
CHF 75 40
Postsurgery 60 38
Post-LTX 67 39
CHFZ congestive heart failure, LTXZ lung transplantation, PPVZ pactivation, are elevated in tuberculous pleural effusions
as opposed to malignant pleural effusions or transudates,
and that SC5be9 levels are highest in patients with
rheumatoid diseases.8,16 Specifically, Hara et al.8 reported
that all patients with tuberculous effusions had SC5be9
levels above 2 mg/L, whereas those with malignant effu-
sions had levels below 2 mg/L. Using this value as the cut-
off, they found that the specificity of the estimated
SC5be9 level for tuberculosis-related effusion was 74%,
and the sensitivity, 100%. In addition, there was a correla-
tion between adenosine deaminase (ADA) and SC5be9
values in the pleural effusions.
In the second study, Salomaa et al.16 found that the
SC5be9 level in the pleural fluid was higher than 2 AU/ml
in all their patients with rheumatic disease and lower
than 2 AU/ml in all their patients with malignancy. Fur-
thermore, the concentrations of pleural fluid C3 and C4
were significantly lower, and the ratio of C4d/C4 signifi-
cantly higher, in the patients with rheumatic pleurisy
than in those with tuberculous or malignant pleurisy. How-
ever, the overlap among the various groups, the relatively
small number of patients with rheumatic effusions, and the
contribution of ADA in differentiating tuberculous from
other effusions limited the diagnostic usefulness of this
test.
Therefore, in the present study, we sought to clarify the
diagnostic value of these products using novel markers. To
the best of our knowledge, this is the only study to assess
complement components in pleural effusions of all known
etiologies, including transudative fluid (as in CHF). In
addition, LTX is nearly always associated with pleural
effusion, usually exudative and bloody, and our study is
the first to assess the pleural complement component
profile in patients after LTX, adding important information
on its clinical implications.17
Our analyses yielded several noteworthy observations.
First, transudative fluids are apparently characterized by
low levels of complement and its components. This findingvalues and accuracy (in %) of C3, C4 and total complement by
NPV PPV Accuracy AUC ROC for no disease
68 44 49 0.435
72 14 25 0.359
92 17 31 0.731
84 10 24 0.367
96 13 30 0.738
61 43 48 0.442
75 14 31 0.337
94 18 39 0.741
83 9 29 0.408
94 13 35 0.678
57 41 47 0.459
76 13 37 0.419
90 18 46 0.673
88 11 40 0.536
90 12 42 0.540
ositive predictive value, NPVZ negative predictive value.
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complement levels and total protein and amylase levels.
Second, CHF-related pleural effusions can be differentiated
from parapneumonic and postsurgery pleural effusions by
the low level of complement. Third, a finding of normal
levels of complement almost completely rule out CHF as an
etiologic factor. Fourth, in patients after LTX, findings of
normal or high pleural fluid complement levels may
indicate that the lung effusion is not attributable to the
surgery, but to another secondary cause (such as
parapneumonic effusions).
On the basis of these findings, we suggest that pleural
complement components should be included in the
assessment of pleural effusion when traditional diagnostic
methods fail.
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